arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CYTOKINETICS INC

CYTK
$75.96 ▼ -2.91 (-3.69%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
28 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
77
Health
Good
Bullish
auto_awesome

Analytical Summary

CYTOKINETICS INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $9.1M
Dividend Yield
Revenue Growth 376.6%
Op. Margin None
ROIC 117.0%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.37
info Valuation on last close. End-of-day price, Aug 6, 2026.

28-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$88.04M
↑ +376.6%
Net Income Profit after all expenses
$-784.96M
↓ -33.2%
Operating Margin Operating profit as % of sales
-342.8%
↓ -29.6%
FCF / Share Free cash flow per share
$-22.41
↓ -475.6%
Long-Term Debt Long-term obligations
$246.38M
↓ -60.2%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
99
Financial Health
64
Cash Quality
48

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 28 years · 77 quarters